Statins and interstitial lung disease: A systematic review of the literature and of food and drug administration adverse event reports

Chest

Volumn 134, Issue 4, 2008, Pages 824-830

  Fernández, Antonio B ^a   Karas, Richard H ^b   Alsheikh Ali, Alawi A ^b   Thompson, Paul D ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARTFORD HOSPITAL   (United States)

Author keywords

Drug induced interstitial lung disease; Hydroxymethylglutaryl coenzyme A reductase inhibitors; Interstitial pneumonitis; Parenchymal lung disease; Pulmonary fibrosis; Statins

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; STEROID;

ADULT RESPIRATORY DISTRESS SYNDROME; ALLERGIC PNEUMONITIS; ALLERGIC REACTION; AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; DERMATOMYOSITIS; DRUG WITHDRAWAL; EOSINOPHILIA; ERYTHEMA; FOOD AND DRUG ADMINISTRATION; HUMAN; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LIPIDOSIS; LUNG FIBROSIS; LUNG FUNCTION; LUNG INFILTRATE; LUPUS LIKE SYNDROME; MEDLINE; PRIORITY JOURNAL; PRURITUS; REVIEW; SIDE EFFECT; SMOKING; SYSTEMATIC REVIEW;

EID: 54249158401     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.08-0943     Document Type: Article

References (34)

1. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998; 279:1643-1650
2. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004; 109(23 suppl 1):III50 -III57
3. Alsheikh-Ali AA, Ambrose MS, Kuvin JT, et al. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation 2005; 111:3051-3057
4. Hill C, Zeitz C, Kirkham B. Dermatomyositis with lung involvement in a patient treated with simvastatin. Aust N Z J Med 1995; 25:745-746
5. Liebhaber MI, Wright RS, Gelberg HJ, et al. Polymyalgia, hypersensitivity pneumonitis and other reactions in patients receiving HMG-CoA reductase inhibitors: a report of ten cases. Chest 1999; 115:886-889
6. De Groot RE, Willems LN, Dijkman JH. Interstitial lung disease with pleural effusion caused by simvastin. J Intern Med 1996; 239:361-363
7. Walker T, McCaffery J, Steinfort C. Potential link between HMG-CoA reductase inhibitor (statin) use and interstitial lung disease. Med J Aust 2007; 186:91-94
8. Sridhar MK, Abdulla A. Fatal lupus-like syndrome and ARDS induced by fluvastatin [letter]. Lancet 1998; 352:114
9. Liscoet-Loheac N, Andre N, Couturaud F, et al. Hypersensitivity pneumonitis in a patient taking pravastatin [in French]. Rev Mal Respir 2001; 18:426-428
10. Lantuejoul S, Brambilla E, Brambilla C, et al. Statin-induced fibrotic nonspecific interstitial pneumonia. Eur Respir J 2002; 19:577-580
11. Veyrac G, Cellerin L, Jolliet P. Un cas de pneumopathie interstitielle rapporte sous atorvastatine (Tahor): synthese des cas publies sous statines. Therapie 2006; 61:57-67
12. Chesnutt M, Murray J, Prendergast P. Interstitial lung disease In: Tierney LM, McPhee SJ, Papadakis MA, eds. Current medical diagnosis and treatment. 46th ed. Available at: http://www.accessmedicine.com. Accessed September 22, 2007
13. Foucher P, Philippe C. The drug-induced lung diseases. Available at: http://pneumotox.com. Accessed November 20, 2007
14. Limper AH, Rosenow EC III. Drug-induced interstitial lung disease. Curr Opin Pulm Med 1996; 2:396-404
15. Limper A. Drug induced pulmonary disease In: Mason RJ, Murray JF, Broaddus VC, eds. Murray and Nadel's textbook of respiratory medicine. 4th ed. Available at: http://www.mdconsult.com. Accessed September 22, 2007
16. Demeter SL, Ahmad M, Tomashefski JF. Drug-induced pulmonary disease: part I. Patterns of response. Cleve Clin Quar 1979; 46:89-99
17. Rossi SE, Erasmus JJ, McAdams HP, et al. Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics 2000; 20:1245-1259
18. Dake MD, Madison JM, Montgomery CK, et al. Electron microscopic demonstration of lysosomal inclusion bodies in lung, liver, lymph nodes, and blood leukocytes of patients with amiodarone pulmonary toxicity. Am J Med 1985; 78: 506-512
19. Lullmann H, Lullmann-Rauch R, Wassermann O. Drug-induced phospholipidoses: II. Tissue distribution of the amphiphilic drug chlorphentermine. CRC Crit Rev Toxicol 1975; 4:185-218
20. Schmien R, Seiler KU, Wassermann O. Drug-induced phospholipidosis: I. Lipid composition and chlorphentermine content of rat lung tissue and alveolar macrophages after chronic treatment. Naunyn-Schmiedeberg's Arch Pharmacol 1974; 283:331-334
21. Bolt MW, Card JW, Racz WJ, et al. Disruption of mitochondrial function and cellular ATP levels by amiodarone and N-desethylamiodarone in initiation of amiodarone-induced pulmonary cytotoxicity. J Pharmacol Exp Ther 2001; 298: 1280-1289
22. Folkers K, Langsjoen P, Willis R, et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci U S A 1990; 87:8931-8934
23. Willis RA, Folkers K, Tucker JL, et al. Lovastatin decreases coenzyme Q levels in rats. Proc Natl Acad Sci U S A 1990; 87:8928-8930
24. Bigazzi PE. Autoimmunity caused by xenobiotics. Toxicology 1997; 119:1-21
25. Fauchais AL, Iba Ba J, Maurage P, et al. Polymyositis induced or associated with lipid-lowering drugs: five cases [in French]. Rev Med Interne 2004; 25:294-298
26. Zuech P, Pauwels C, Duthoit C, et al. Pravastatin-induced dermatomyositis [in French]. Rev Med Interne 2005; 26:897-902
27. Dourmishev AL, Dourmishev LA. Dermatomyositis and drugs. Adv Exp Med Biol 1999; 455:187-191
28. Ahmad S. Lovastatin-induced lupus erythematosus. Arch Intern Med 1991; 151:1667-1668
29. Yoshioka S, Mukae H, Ishii H, et al. A case of drug-induced pneumonia possibly associated with simvastatin [in Japanese]. Nihon Kokyuki Gakkai Zasshi 2005; 43:600-604
30. Watts KL, Sampson EM, Schultz GS, et al. Simvastatin inhibits growth factor expression and modulates profibrogenic markers in lung fibroblasts. Am J Respir Cell Mol Biol 2005; 32:290-300
31. Watts KL, Cottrell E, Hoban PR, et al. RhoA signaling modulates cyclin D1 expression in human lung fibroblasts; implications for idiopathic pulmonary fibrosis. Respir Res 2006; 7:1-14
32. Tan A, Levrey H, Dahm C, et al. Lovastatin induces fibroblast apoptosis in vitro and in vivo: a possible therapy for fibroproliferative disorders. Am J Respir Crit Care Med 1999; 159:220-227
33. Alexeeff SE, Litonjua AA, Sparrow D, et al. Statin use reduces decline in lung function: VA Normatice Aging Study. Am J Respir Crit Care Med 2007; 176:742-747
34. Nadrous HF, Ryu JH, Douglas WW, et al. Impact of angiotensin-converting enzyme inhibitors and statins on survival in idiopathic pulmonary fibrosis. Chest 2004; 126:438-446